Effects of Renin-Angiotensin-Aldosterone System Blockade on Chlorhexidine Gluconate-Induced Sclerosing Encapsulated Peritonitis in Rats
- 17 January 2012
- journal article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 16 (1) , 75-80
Abstract
Sclerosing encapsulated peritonitis (SEP) is a rare complication of long term peritoneal dialysis. Renin-angiotensin-aldosterone system (RAAS) may play a role in the development of peritoneal fibrosis in CAPD patients. We aimed to evaluate the effect of aliskiren, valsartan, and aliskiren + valsartan therapy on SEP. The study included 30 Wistar albino rats which were divided into five groups: I (Control) SF solution i.p.; II (CG group) chlorhexidine gluconate i.p.; III aliskiren oral plus CG i.p.; IV valsartan oral plus CG i.p.; and V aliskiren oral, valsartan oral and CG i.p. On the twenty-first day, all of the rats were sacrificed. All of the groups were analyzed in terms of peritoneal thickness, degree of inflammation, vasculopathy, neovascularization and fibrosis. Also, the parietal peritoneal tissue samples were evaluated for matrix metalloproteinase 2 (MMP-2) using the ELISA method. Peritoneal thickness and fibrosis scores were lower in the valsartan group compared to the CG group (P < 0.05). Peritoneal fibrosis scores were lower in the aliskiren group compared to CG group (P < 0.05) but no difference was observed between the peritoneal thickness scores of the two groups (P > 0.05). Tissue MMP-2 levels were significantly higher in the CG group compared other groups (P < 0.05). There were no statistically significant differences between the aliskiren, valsartan and aliskiren + valsartan groups according to the tissue MMP-2 levels. Due to the antifibrotic properties of valsartan, it is thought to be a possible choice to prevent SEP development. We found no positive impact of aliskiren or aliskiren + valsartan combination compared to valsartan alone.Keywords
This publication has 15 references indexed in Scilit:
- Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in ratsCytokine, 2011
- A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskirenAmerican Journal of Physiology-Renal Physiology, 2010
- Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategiesJournal Of Hypertension, 2010
- Aliskiren ameliorates chlorhexidine digluconate‐induced peritoneal fibrosis in ratsEuropean Journal of Clinical Investigation, 2010
- Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardiumBiochemical and Biophysical Research Communications, 2009
- Role of the renin-angiotensin system in autoimmune inflammation of the central nervous systemProceedings of the National Academy of Sciences, 2009
- Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patientsBritish Journal of Cancer, 2007
- Interactions of Transforming Growth Factor-β and Angiotensin II in Renal FibrosisHypertension, 1998
- Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.Journal of Clinical Investigation, 1996
- Role of aldosterone in the remnant kidney model in the rat.Journal of Clinical Investigation, 1996